top of page

Legacy Investments

These are prior Capital Midwest Fund (CMF) investments that are not representative of CMF's strategy going forward. CMF no longer invests in pre-clinical or clinical-stage companies.

Legacy Investments: Portfolio
Gemphire Therapeutics.png

IPO - Exited Position

Gemphire Therapeutics was a clinical-stage biopharmaceutical company focused on cardiometabolic disorders, including dyslipidemia and NASH. In December 2019, Gemphire Therapeutics merged with NeuroBo Pharmaceuticals (NASDAQ: NRBO), which is the surviving entity.

Ocuphire Pharma.png

Reverse Merger

Ocuphire Pharma is a clinical-stage biopharmaceutical company focused on a variety of ophthalmic disorders. The company's lead drug candidate is a once-daily eye drop, Nyxol®, to treat multiple front-of-the-eye disorders, including night vision disturbances, pharmacologically-induced mydriasis, and presbyopia.

PreEmptive Meds.png

PMI’s products represent viable options for preempting disease or assisting in medical treatment and are supported by meaningful clinical data.

Rapid Diagnostek.png


Rapid Diagnostek developed a patented, point-of-care, biosensor-based platform appropriate for detecting proteins, bacteria, viruses, and other substances contained in liquid samples. Rapid Diagnostek was acquired by Qorvo in 2016.

SeaStar Medical.png


SeaStar Medical's products focus on treating acute, inflammatory-driven conditions.

Sierra Oncology.png

IPO - Acquired

Sierra Oncology is a biotechnology company developing therapeutics for the treatment of hematology and oncology.



TPI focused on making biosimilar medications affordable by developing a proprietary, single-use technology platform, MayaBio®, to build a strong pipeline of biosimilar candidates. TPI renamed to Adello Biologics in 2016 and was acquired by Kashiv BioSciences in 2019.


10556 N Port Washington Rd
Ste 201
Mequon, WI 53092

(414) 453-4488

Legacy Investments: Contact
bottom of page